- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- Careers
- News & Insights
- About
- Languages
People
Geoff Leonard focuses his practice on the representation of technology companies, including life science companies. Geoff is a partner in our Corporate Governance and Mergers & Acquisitions practices, with considerable experience in the areas of securities and corporate finance, including equity and debt offerings, mergers and acquisitions, venture capital, private equity and strategic alliances.
Geoff counsels technology companies, particularly in life sciences, concerning securities and corporate finance matters, and handles equity and debt offerings, mergers and acquisitions, venture capital, private equity and strategic alliances. He also advises public companies on securities matters, as well as in ongoing Securities and Exchange Commission reporting matters.
In addition, Geoff regularly serves venture-backed companies as principal outside counsel. He has been counsel to numerous companies at every life-cycle stage, from incorporation through venture funding and final exit, as well as to the investors that finance these companies.
Geoff was recognized by Legal 500 in 2016 and 2020 in Healthcare: Life Sciences and in two M&A categories—Middle Market and Venture Capital and Emerging Companies. He also was cited by Corporate INTL as Technology Sector M&A Attorney of the Year in California for 2014, and by Finance Monthly as a 2012 Deal Maker of the Year.
Credentials
J.D., Georgetown University Law Center, cum laude
B.A. History, Trinity College
California
New York
Close
Recognition
Healthcare: Life Sciences
Legal 500, 2016 and 2020
M&A: Middle Market
Legal 500, 2016 and 2020
M&A: Venture Capital and Emerging Companies
Legal 500, 2016 and 2020
Technology Sector M&A Attorney of the Year, California
Corporate INTL, 2014
2012 Deal Maker of the Year
Finance Monthly
News
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Cases & Deals
August 1, 2018
King & Spalding Advises Claret Medical on $270 Million Acquisition by Boston Scientific Corp.
Recognition
July 8, 2016
Legal 500 U.S. Ranks King & Spalding Practices and Lawyers Among the Best in 2016
Matters
Represented Claret Medical in its sale to Boston Scientific Corporation for $270 million.
Represented Apama Medical from inception through its subsequent sale to Boston Scientific Corporation for up to $300 million.
Represented C2 Therapeutics from inception through its subsequent sale to Hoya Corporation.
See more
Close
Matters
Represented Claret Medical in its sale to Boston Scientific Corporation for $270 million.
Represented Apama Medical from inception through its subsequent sale to Boston Scientific Corporation for up to $300 million.
Represented C2 Therapeutics from inception through its subsequent sale to Hoya Corporation.
Represented Vector Laboratories in its sale to the private equity firm GTCR.
Represented Lightstone Ventures as joint investors along with New Enterprise Associates and Medtronic in a new company, FIRE1, launched by The Foundry, a premier medical device incubator.
Represented Access Closure from inception through its subsequent sale to Cardinal Health for $320 million.
Represented Sadra Medical from inception through its venture financings and in its subsequent sale to Boston Scientific for up to $450 million.
Represented Nestle S.A. in its joint venture with The Coca-Cola Company for the worldwide marketing and sale of Nestea.
Represented TPG Opportunity Partners and Clarus Ventures in their acquisition and subsequent sale of a royalty interest of Gilead Sciences.
Represented Skire, Inc. in its sale to Oracle Corp.
Insights
Client Alert
October 3, 2018
California Enacts Law Requiring Female Representation on Boards
News
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Cases & Deals
August 1, 2018
King & Spalding Advises Claret Medical on $270 Million Acquisition by Boston Scientific Corp.
Recognition
July 8, 2016
Legal 500 U.S. Ranks King & Spalding Practices and Lawyers Among the Best in 2016
Matters
Represented Claret Medical in its sale to Boston Scientific Corporation for $270 million.
Represented Apama Medical from inception through its subsequent sale to Boston Scientific Corporation for up to $300 million.
Represented C2 Therapeutics from inception through its subsequent sale to Hoya Corporation.
See more
Close
Matters
Represented Claret Medical in its sale to Boston Scientific Corporation for $270 million.
Represented Apama Medical from inception through its subsequent sale to Boston Scientific Corporation for up to $300 million.
Represented C2 Therapeutics from inception through its subsequent sale to Hoya Corporation.
Represented Vector Laboratories in its sale to the private equity firm GTCR.
Represented Lightstone Ventures as joint investors along with New Enterprise Associates and Medtronic in a new company, FIRE1, launched by The Foundry, a premier medical device incubator.
Represented Access Closure from inception through its subsequent sale to Cardinal Health for $320 million.
Represented Sadra Medical from inception through its venture financings and in its subsequent sale to Boston Scientific for up to $450 million.
Represented Nestle S.A. in its joint venture with The Coca-Cola Company for the worldwide marketing and sale of Nestea.
Represented TPG Opportunity Partners and Clarus Ventures in their acquisition and subsequent sale of a royalty interest of Gilead Sciences.
Represented Skire, Inc. in its sale to Oracle Corp.
Insights
Client Alert
October 3, 2018
California Enacts Law Requiring Female Representation on Boards
News
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Cases & Deals
August 1, 2018
King & Spalding Advises Claret Medical on $270 Million Acquisition by Boston Scientific Corp.
Recognition
July 8, 2016
Legal 500 U.S. Ranks King & Spalding Practices and Lawyers Among the Best in 2016
Credentials
J.D., Georgetown University Law Center, cum laude
B.A. History, Trinity College
California
New York
Close
Recognition
Healthcare: Life Sciences
Legal 500, 2016 and 2020
M&A: Middle Market
Legal 500, 2016 and 2020
M&A: Venture Capital and Emerging Companies
Legal 500, 2016 and 2020
Technology Sector M&A Attorney of the Year, California
Corporate INTL, 2014
2012 Deal Maker of the Year
Finance Monthly